‘Lipodystrophy syndrome’ in the setting of HIV infection has come to encompass a collection of morphological and metabolic abnormalities linked with the use of antiretroviral therapy and other risk factors. We review the clinical literature on this subject as it has evolved historically, taking pertinent methodological issues into account.
References
1.
MassipP., MarchouB., BonnetE., CuzinL., & MontastrucJ.L.Lipodystrophia with protease inhibitors in HIV patients. Therapie1997; 52: 615.
HerryI., BernardL., de TruchidP., & PerroneC.Hypertrophy of the breasts in a patient treated with indinavir. Clinical Infectious Diseases1997; 25: 937–938.
5.
LuiA., KarterD., & TurettG.Another case of breast hypertrophy in a patient treated with indinavir (letter). Clinical Infectious Diseases1998; 26: 1482.
6.
LoJ.C., MulliganK., TaiV.W., AlgrenH., & SchambelanM.‘Buffalo hump’ in men with HIV-1 infection. Lancet1998; 351: 867–870.
7.
WurtzR.Abnormal fat distribution and use of protease inhibitors (letter). Lancet1998; 351: 1735–1736.
8.
RothV.R., KravcikS., & AngelJ.B.Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clinical Infectious Diseases1998; 27: 65–67.
CarrA., & CooperD.A.Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. New England Journal of Medicine1998; 339: 1296.
17.
DonovanB., BodsworthN.J., MulhallB.P., & AllenD.Gynaecomastia associated with saquinavir therapy. International Journal for the Study of AIDS1999; 10: 49–50.
18.
SchurmannD., BergmannF., EhrensteinT., & PadbergJ.Gynaecomastia in a male patient during protease inhibitor treatment for acute HIV disease (letter). AIDS1998; 12: 2232–2233.
19.
GervasoniC., RidolfoA.L., TrifiroG., SantambrogioS., NorbiatoG., MusiccoM., ClericiM., GalliM., & MoroniM.Redistribution of body fat in HIV infected women undergoing combined antiretroviral therapy. AIDS1999; 13: 465–471.
20.
SmithK., GermainM., DeckerC., YeagerJ., & SkeltonH.Increased soft tissue in posterior cervical and upper back area of patients on HIV-1 protease inhibitors. Journal of Cutaneous Medicine and Surgery1999; 3: 211–217.
21.
MulliganK., Grunfeld, TaiV.W., AlgrenH., PangM., ChernoffD.N., LoJ.C., & SchambelanM.Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of change in body composition in patients with HIV infection. Journal of AIDS2000; 23: 35–43.
22.
SullivanA.K., & NelsonM.R.Marked hyperlipidemia on ritonavir therapy. AIDS1997; 11: 938–939.
23.
ChurchillD.R., PymA.S., BabikerA.G., BackD.J., & WeberJ.N.Hyperlipidemia following treatment with protease inhibitors in patients with HIV-1 infection. British Journal of Clinical Pharmacology1998; 46: 518–519.
DongK.L., BaussermanL.L., FlynnM.M., DickinsonB.P., FlaniganT.P., MilenoM.D., TashimaK.T., & CarpenterC.C.Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). Journal of Acquired Immune Deficiency Syndrome1999; 21: 107–113.
26.
BehrensG., DejamA., SchmidtH., BalksH.J., BrababtG., KornerT., StollM., & SchmidtR.E.Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS1999; 13: 63F–70F.
27.
SchmidtHH-J, BehrensG., & GenschelJ.Lipid evaluation in HIV-1-positive patients treated with protease inhibitors. Antiviral Therapy1999; 4: 163–170.
28.
EchevarriaK.L., HardinT.C., & SmithJ.A.Hyperlipidemia associated with protease inhibitor therapy. Annals of Pharmacotherapy1999; 33: 859–863.
29.
PeriardD., TelentiA., SudreP., CeseauxJ.J., HalfonP., ReymondM.J., MarcovinaS.M., GlauserM.P., NicodP., DarioliR., & MooserV.Atherogenic dyslipidemia in HIV infected individuals treated with protease inhibitors. Circulation1999; 100: 700–705.
30.
SergererS., BognerJ.R., WalliR., LochO., & GoebelF.D.Hyperlipidemia under treatment with proteinase inhibitors. Infection1999; 27: 77–81.
31.
BertholdH.K., ParhoferK.G., RitterM.M., AddoM., WasmuthJ.C., SclieferK., SpenglerU., & RockstrohJ.K.Influence of protease inhibitor therapy on lipoprotein metabolism. Journal of Internal Medicine1999; 246: 567–575.
32.
TsiodrasS., MantzorosC., HammerS., & SamoreM.Effects of protease inhibitors on hyperglyceamia, hyperlipidaemia, and lipodystrophy. A 5-year cohort study. Archives of Internal Medicine2000; 160: 2050–2056.
WalliR., HerfortO., MichlG.M., DemantT., JagerH., DieterleC., BognerJ.R., LandgrafR., & GoebelF.D.Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS1998; 12: 167F–173F.
38.
YarasheskiK.E., TebasP., SigmundC., Dagogo-JackS., BohrerA., TurkJ., HalbanP.A., CryerP.E., & PowderlyW.G.Insulin resistance and HIV protease inhibitor-associated diabetes. Journal of AIDS1999; 21: 209–216.
39.
MiroJ.M., MartinezE., GarciaF., LozanoL., AlsinaM., TortajadaC., PlanaM., GallertT., VidalC., PumarolaT., MallolasJ., & GattellJ.M.Incidence of lipodystrophy in patients with primary HIV-1 infection (PHI) treated with HAART. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 12.
40.
MillerJ., CarrA., SmithD., EmeryS., LawM.G., GreyP., & CooperD.A.Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS2000; 14: 2406–2407.
KasperT.B., ArbeolaC.H., & HalpernM.The impact of patient perceptions of body shape changes and metabolic abnormalities on antiretroviral therapy.Programs and Abstracts of the XIII International AIDS Conference, Durban, South Africa, 9–14 July 2000. Abstr. ThOrB762.
43.
GoetzenichA., CorzillusM., MaussS., SchwenkA., WolfE., BeckmannR., JagerH., KnechtenH., & LocherL.Impact of lipodystrophy on quality of life.Programs and Abstracts of the XIII International AIDS Conference, Durban, South Africa, 9–14 July 2000. Abstr. ThPpB1437.
BehrensG., SchmidtH., MeyerD., StollM., & SchmidtR.E.Vascular complications associated with use of HIV protease inhibitors (letter). Lancet1998; 351: 1958.
46.
GalletB., PulikM., GenetP., ChedinP., & HiltgenM.Vascular complications associated with use of HIV protease inhibitors (letter). Lancet1998; 351: 1958–1959.
47.
VittecoqD., EscautL., & MonsuezJ.J.Vascular complications associated with use of HIV protease inhibitors (letter). Lancet1998; 351: 1959.
48.
LaurenceJ.Vascular complications associated with use of HIV protease inhibitors (letter). Lancet1998; 351: 1960.
49.
SoRelleR.Vascular and lipid syndromes in selected HIV-infected patients. Circulation1998; 98: 829–830.
50.
ErikssonU., OpravilM., AmannF.W., & SchaffnerA.Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients?AIDS199812: 2079–2080.
51.
SullivanA.K., NelsonM.R., & MoyleG.J.Coronary artery disease occurring with protease inhibitor therapy (letter). International Journal for the Study of AIDS1998; 9: 711–712.
52.
JutteA., SchwenkA., FranzenC., RomerK., DietV., FatkenheuerG., & SalzbergerB.Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment. AIDS1999; 13: 1796–1797.
53.
FlynnT.E., & BrickerL.A.Myocardial infarction in HIV-infected men receiving protease inhibitors. Annals of Internal Medicine1999; 131: 548.
54.
CarrA., SamsarasK., BurtonS., LawM., FreundJ., ChisholmD.J., & CooperD.A.A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving protease inhibitors. AIDS1998; 12: 51F–58F.
55.
CarrA., SamsarasK., ChisholmD.J., & CooperD.A.Pathogenesis of HIV-1 protease inhibitor associated peripheral lipodystrophy, hyperlipidemia and insulin resistance. Lancet1998; 351: 1881–1881.
56.
CarrA., SamsarasK., ThorisdottirA., KaufmannG.R., ChisholmD.J., & CooperD.A.Diagnosis, prediction, and natural course of HIV-1 protease inhibitor associated lipodystrophy, hyperlipidemia and diabetes mellitus: A cohort study. Lancet1999; 353: 2093–2099.
57.
SafrinS., & GrunfeldC.Fat distribution and metabolic changes in patients with HIV infection. AIDS1999; 13: 2493–2505.
58.
BensonJ., McGheeK., CoplanP., GrunfeldC., RobertsonM., Groodnow BrodoviczK., & SlaterE.Fat redistribution in indinavir treated patients with HIV infection: a review of postmarketing cases. Journal of AIDS2000; 25: 130–139.
Saint-MarcT., PartisaniM., Poizot-MartinI., RouviereO., BrunoF., LangJ.M., GastautJ.A., & TouraineJ.L.Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPICO study. AIDS2000; 14: 37–49.
61.
MadgeS., Kinloch-de-LoesS., MerceyD., JohnsonM.A., & WellerI V.Lipodystrophy in patients naive to HIV protease inhibitors. AIDS1999; 13: 735–737.
62.
CarrA., MillerJ., LawM., & CooperD.A.A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS2000; 14: 25–32.
63.
MallalS.A., JohnM., MooreC.B., JamesI.R., & McKinnonE.J.Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS2000; 14: 1309–1316.
64.
GalliM., RidolfoA.L., RavasioL., GervesoniC., CorsicoL., AdorniF., SantabrogioS., D'Arminio MonteforteA., & MoroniM.Cumulative time-dependant probability of developing fat tissue alterations in female patients treated with combined antiretroviral therapy. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 28.
65.
KotlerD.P., TheaD.M., HeoM., AllisonD.B., EngelsonE.S., WangJ., PiersonR.N., St LouisM., & KeuschG.T.Relative influences of sex, race, environment, and HIV infection on body composition in adults. American Journal of Clinical Nutrition1999; 69: 432–439.
66.
El-SadrW.M., CollinsG., RaghavanS., RappaportC., GilbertC., CarrA., & BartschG.Prevalence of metabolic complications in a large diverse cohort of HIV-infected persons. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 13.
67.
WankeC., JacobsenD., KnoxT., & GorbachS.Prevalence of fat deposition and fat atrophy in a cohort of HIV infected men and women. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 24.
68.
FalutzJ., MuurahainenN., WorkmanC., BalserJ., KleintopM., PettitR., & KotlerD.Gender is associated with increased body size but not fat depletion in patients with HIV-associated adipose redistribution syndrome (HARS).Program and Abstracts of the XIIIth International AIDS Conferance, Durban, South Africa, 9–14 July 2000. Abstr. WePeB4273.
69.
RaghavanS., AidaryA.H., LesterK., SantosS., WangJ., MedardF., & El-SadrW.Gender differences in prevalence of body habitus changes and metabolic complications in HIV+ African American and Latino individuals from Harlem. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 27.
70.
MaussS., CorzillusM., WolfE., SchwenkA., JaegerH., KnechtenH., GoelzJ., & GoetzenichA.Risk factors for HIV-associated lipodystrophy syndrome in patients with uniform duration of antiretroviral treatment (LipART).Program and Abstracts of the 2ndInternational Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13–15 September 2000. Abstr. P68.
71.
PoloR., VerdejoJ., Martinez-RodriuezS., & MadrigalP.Lipodystrophy in protease inhibitor-naïve HIV-infected patients. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17–20 September 2000. Abstr. 1282.
72.
ScarsellaA.J., DieterichD.T., GrahamN.M.H., FuscoG.P., SherrillB.H., FuscoJ.S., HansenN.I., & BeckerS.L.Predictors of lipodystrophy in HIV-infected patients from the CHORUS observational cohort. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17–20 September 2000. Abstr. 1286.
73.
CarrA., & CooperD.A randomised, multicentre study of protease inhibitor (PI) substitution in aviremic patients with antiretroviral (ARV) lipodystrophy syndrome. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 205.
74.
EngelsonE.S., KotlerD. P., TanY., AginD., WangJ., PiersonR.N., & HeymsfieldS.B.Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole body magnetic resonance imaging. American Journal of Clinical Nutrition1999; 69: 1162–1169.
75.
MartinezE., BianchiL., GarciaM.A., BruC., & GattellJ.M.Assessment of regional fat thickness by sonography in HIV-infected patients with lipodystrophy.Program and Abstracts of the XIII International AIDS Conference, Durban, South Africa, 9–14 July 2000. Abstr. ThPeB5043.
76.
PurnellJ.Q., ZambonA., KnoppR.H., PizzutiD.J., AchariR., & LeonardJ.M.Effect of ritonavir on lipids and post-heparin lipase in normal subjects. AIDS2000; 14: 51–57.
77.
Italian Registry of Post-Exposure Prophylaxis.Effect of short-course of antiretroviral agents on serum triglycerides of healthy adults. AIDS2000; 14: 2407–2408.
78.
FetterA., NacciP., LenhardJ., WhiteA., PaganoG., DhamuS., & RogersM.D.Fat distribution and retinoid-like symptoms are infrequent in NRTI experienced subjects treated with amprenavir. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 18.
79.
MartinezE., CongetI., LozanoL., CasamitjanaR., & GatellJ.M.Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS1999; 13: 805–810.
80.
RuizL., NegredoE., DomingoP., Bonjoch, ParedesR., FranciaE., BalagueM., RomeuJ., ArnoA., FumazC.R., JohnstonS., SireraG., TuralC., & ClotetB.Clinical, virological, and immunological benefit of switching the protease inhibitor (PI) by nevirapine (NVP) in HAART experienced patients suffering lipodystrophy (LD): 36-week follow up. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 206.
81.
TebasP., YarasheskiK., HenryK., KaneE., MarinD., SimpsonJ., ClaxtonS., KlebertM., & PowderlyW.G.Evolution of multiple metabolic parameters after the switch of protease inhibitors to nevirapine.Program and Abstracts of the XIII International AIDS Conference, Durban, South Africa, 9–14 July 2000. Abstr. ThPpB1485.
82.
GoebalF., & WalliR.K.A novel use of abacavir to simplify therapy in PI-experienced patients successfully treated with HAART: CNA30017. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 51.
83.
RozenbaumW., MolinaJ.M., DelfraissyJ.F., BentataJ.M., De TruchisP., & AntounZ.Improvement of lipodystrophy in HIV-infected subjects switching from 2 NRTI/PI to 2 NRTI/Abacavir (French substudy, CNA30017). Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000, Abstr. 47.
84.
WalliR., HusterK., BognerJ.R., & GoebelF.D.Switching from PI to ABC improves insulin sensitivity and fasting lipids – 12-month follow-up. Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 4–8 February. Abstr. 672.
85.
MoyleG.J., BaldwinC., ComitisS., DentN., & GazzardB.G.Changes in visceral adipose tissue and blood lipids in persons reporting fat redistribution syndrome switched from PI therapy to efavirenz. Antiviral Therapy1999; 4 (Suppl. 2): 64. (Abstr. 55.).
86.
GharakhanianS., SalhiY., AddaN., VigourouxC., CapeauJ., & RozenbaumW.Identification of fat redistribution/ metabolic anomalies in a cohort treated by 2 NRTIS +1 PI, and absence of significant modification following PI substitition. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 46.
87.
BonnetE., LepecR., BluteauM., HerveR., BernardJ., PerretJ., IzopetJ., & MassipP.Evolution of lipodystrophy syndrome and lipidic profile in HIV patients after switching from protease inhibitors to efavirenz. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 49.
88.
MartinezE., BlancoJ.L., & GarciaM.A.Impact of switching from protease inhibitors (PI) to efavirenz (EFV) in patients with lipodystrophy. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 50.
89.
VicianaP., AlarconA., MartinD., SerranoP., Lopez-CortesL.F., CoderoE., & Gomez-VeraM.J.Partial improvement of lipodystrophy after switching from protease inhibitors (PI) to efavirenz (EFV). Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 48.
90.
EstradaV., De VillarN.G.P., Martinez-LarradT., TellezM.J., & Serrano-RiosM.Switching to efavirenz from protease inhibitor-based therapy does not improve insulin resistance after one year in HIV patients with lipodystrophy syndrome. Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 4–8 February 2001. Abstr. 671.
91.
MolinaJ.M., AngeliniE., CotteL., LangJ.M., MorlatP., RancinanC., MayT., JournotV., RaffiF., JarrousseB., GrappinM., LepeuG., & CheneG.Prevalence of lipodystrophy in long term follow up of a clinical trial comparing various combinations of nucleoside analogue reverse transcriptase inhibitors (NRTI), ALBI trial:ANRS 070. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 19.
92.
LawM., EmeryS., FrenchM., CarrA., ChuahJ., & CooperD.Lipodystrophy and metabolic abnormalities in a cross-sectional study of participants in randomised controlled studies of combination antiretroviral therapy.Program and Abstracts of the 2ndInternational Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13–15 September 2000. Abstr. 028.
93.
JolyV., FlandreP., MeiffredyV., HazebrouckS., HarelM., AboulkerJ.P., & YeniP.Assessment of lipodystrophy in patients previously exposed to AZT, ddI or ddC, but naïve for d4T and protease inhibitors (PI), and randomised between d4T/3TC/Indinavir and AZT/3TC/Indinavir (NOVAVIR trial). Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 4–8 February 2001. Abstr. 539.
94.
Saint MarcT., & TouraineJ.L.The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS1999; 13: 2188–2189.
95.
PoloR., VerdejoJ., Gonzalez-MunozM., Gomez-CanoM., Martinez-GarridoS., Martinez-RodriguezS., & Gonzalas-LahozJ.Switch to AZT plus 3TC improves lipodystrophy in the presence of protease inhibitors. Program and Abstracts of 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif., USA, 26–29 September 1999. Abstr. 1306.
96.
Van der WalkM., GisolfE., ReissP., WitF., JapourA., WeverlingG., & DannerS.Increased risk of lipodystrophy when including NRTIs in the treatment of HIV-1 infection with protease inhibitors: results from a randomised controlled trial.Program and Abstracts of the 2ndInternational Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13–15 September 2000. Abstr. P78.
97.
CohenC., CameronW., XuY., RodeR., MellorsJ., FarthingC., PoretzD., MarkovitzD., HoD., McMahonD., DrennonD., SelnessK., RyanJ., SunE., & JapourA.J.Effect of NRTI intensification on prevalence of body composition abnormalities at week 144 of ritonavir plus saquinavir therapy in an HIV-infected cohort.Program and Abstracts of the 2ndInternational Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13–15 September 2000. Abstr. P56.
98.
GalliM., RidolfoA.L., GervasoniC., SantambrogioS., RavasioL., CorsicoL., GianelliE., D'Armino MontforteA., AdorniF., & MoroniM.Risk of developing metabolic alterations in PI-naïve HIV-1 infected patients treated with NRTI. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17–20 September 2000. Abstr. 1292.
99.
WitF., GisolfE.H., OostweegalL.M.M., WeverlingG.J., LangeJ.M.A., ReissP., & DannerS.A.Stavudine use is not associated with an incremental risk of hyperlipidemia during treatment with HIV-1 protease inhibitors.Program and Abstracts of the 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, Calif., USA, 26–28 June 1999. Abstr. 065.
100.
GalliM., VegliaF., AngaranoG., CargnelA., GrittiF., MazzottaF., & LazzarinA.Risk factors associated with types of metabolic and morphological alterations according to the Marrakech classification.Program and Abstracts of the 2ndInternational Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13–15 September 2000. Abstr. P61.
101.
HadiganC., MeigsJ.B., CorcoranC., RietschelP., PiecuchS., BasgozN., DavisB., SaxP., StanelyT., WilsonP. W., D'AgostinoR.B., & GrinspoonS.Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clinical Infectious Diseases2001; 32: 130–139.
102.
HadiganC., MillerK., CorcoranC., AndersonE., BasgozN., & GrinspoonS.Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. Journal of Clinical Endocrinology and Metabolism1999; 84: 1932–1937.
103.
LopesJ., EngelsonE.S., WangJ., AginD., HeymsfieldS.B., & KotlerD.P.Interaction among sex, HIV infection and fat redistribution.Program and Abstracts of the 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13–15 September 2000. Abstr. P29.
104.
LichtensteinK.A., DelaneyK.M., WardD.J., & PalellaF.J.Clinical factors associated with incidence and prevalence of fat atrophy and accumulation.Program and Abstracts of the 2ndInternational Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13–15 September 2000. Abstr. P64.
105.
RossR., LegerL., MorrisD., de GiuseJ., & GuardoR.Quantification of adipose tissue by MRI: relationship to anthropometric variables. Journal of Applied Physiology1992; 72: 787–795.
106.
RexrodeK.M., CareyV.J., HennekensC.H., WaltersE.E., ColditzG.A., StampferM.J., WillettW.C., & MansonJ.E.Abdominal obesity and coronary heart disease in women. Journal of the American Medical Association1998; 280: 1843–1848.
107.
HadiganC., CorcoranC., PiecuchS., RodriguezW., & GrinspoonS.Hyperandrogenemia in human immunodeficiency virus-infected women with the lipodystrophy syndrome. Journal of Clinical Endocrinology Metabolism2000; 85: 3544–3550.
108.
EkongE., UwahA., & AkanmuA.Prevalence of lipodystrophy syndrome in a cohort of patients exposed to antiretroviral drug therapy.Program and Abstracts of the 2ndInternational Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13–15 September 2000. Abstr. O16.
109.
ChangK., KimJ., HongS., SongY., LeeH., & LimS.Does race protect an Oriental population from developing lipodystrophy in HIV-infected individuals on HAART? Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, USA, 4–8 February 2001. Abstr. 648.
110.
PatonN., AboulhabJ., NgY-M, KarimF., & LeeC-CPrevalence of lipodystrophy in a cohort of Asian HIV patients.Program and Abstracts of the 2ndInternational Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13–15 September 2000. Abstr. O15.
111.
FraserH.E., IshiharaM., MillerJ.E., LawM., YasuokaA., KikuchiY., TachikawaN., GenkaI., TeruyaK., WatanabeM., & OkaS.Prevalence survey of lipodystrophy in HIV-positive patients in Japan.Program and Abstracts of the 2ndInternational Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13–15 September 2000. Abstr. O17.
112.
KleinD., HurleyL., & SidneyS.Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients? Additional follow-up.Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 33.
113.
CoplandP., CormierK., JapourA., Maradit-KremersH., NikasA., LewisR., & XuY.Myocardial infarction incidence in clinical trials of 4 protease inhibitors.Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 34.
114.
Mary-KrauseM., CotteL., PartisaniM., SimonA., & CostagliolaD.Impact of treatment with protease inhibitor on myocardial infarction occurrence in HIV-infected men.Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 4–8 February 2001. Abstr. 657.
115.
RossR.Atherosclerosis – an inflammatory disease. New England Journal of Medicine1999; 340: 115–126.
116.
MaggiP., SerioG., EpifaniG., FiorentinoG., SaracinoA., FicoC., PerilliF., LilloA., FerraroS., GargiuloM., ChirianniA., AngaranoG., ReginaG., & PastoreG.Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS2000; 14: 123–128.
117.
Lenormand-WalckenaerC., CazaubonM., JolyV., MatheronS., PorcherR., & PrevotM.Carotid intima media thickness in protease inhibitor-treated HIV-1-infected patients with hyperlipemia.Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17–20 September 2000. Abstr. 1298.
118.
PanA., SeminariE., VoltiniG., MaseratiR., TinelliC., MeneghettiG., Carnevale, & TestaS.Intima media thickness as cardiovascular risk marker in HIV-positive patients treated and untreated with protease inhibitors.Program and Abstracts of the 2ndInternational Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13–15 September 2000. Abstr. O25.
119.
SosmanJ.M., KleinM.A., BellehumeurJ.L., AeschlimannS.E., & SteinJ.H.Endothelial dysfunction is associated with use of human immunodeficiency virus-1 protease inhibitors.Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, January 30 – February 2 2000. Abstr. 29.
120.
WeberT-J, BengelF., BognerJ-R, LeberA., HaberlR., SchwaigerM., & GoebelF-DCardiovascular dysregulation in HIV-infected individuals treated with HAART.Program and Abstracts of the 2ndInternational Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13–15 September 2000. Abstr. O26.
121.
TalwaniR., FalusiO.M., Mendes de LeonC.F., NeradJ.L., RichS., ProiaL.A., ShaB.E., SmithK.Y., & KesslerH.A.Electron beam computed tomography for assessment of coronary artery disease in HIV-infected males on antiretroviral therapy.Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17–20 September 2000. Abstr. 1299.
122.
HenryK., MelroeH., HuebschJ., HermundsonJ., & SimpsonJ.Atorvastatin and gemfibrozil for protease inhibitor-related lipid abnormalities (letter). Lancet1998; 352: 1031–1032.
MoyleG.J., LloydM., ReynoldsB., & BaldwinC.A randomised open label comparative trial of dietary advice with or without pravastatin for the management of protease inhibitor (PI)-associated hypercholesterolemia.Program and Abstracts of the XIII International AIDS Conference, Durban, South Africa, 9–14 July 2000. Abstr. ThPpB1438.
125.
BaldiniF., Di GiamebedettoS., CingolaniA., MurriR., AmmassariA., & De LucaA.Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidemias:a pilot study.Program and Abstracts of the XIII International AIDS Conference, Durban, South Africa, 9–14 July 2000. Abstr. WePeB4277.
126.
DubeM.P., SprecherD., HenryW.K., AbergJ.A., TorrianiF.J., HodisH.N., SchoutenJ., LevinJ., MyersG., ZackinR., NevinT., & CurrierJ.S.Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the adult AIDS clinical trial group cardiovascular disease focus group. Clinical Infectious Diseases2000; 31: 1216–1224.
127.
FichtenbaumC., GerberJ., RosenkranzS., SegalY., BlaschkeJ., AbergM., RoyalW., BurningW., LambK., FergusonE., AlstonB., & AweekaF.Pharmacokinetic interaction between protease inhibitors and selected HMG-CoA reductase inhibitors.Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. LB6.
128.
MillerJ., CarrA., BrownD., & CooperD.A.A randomized double-blind study of gemfibrozil (GF) for the treatment of protease inhibitor associated hypertriglyceridemia.Programme and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 4–8 February 2001. Abstr. 540.
129.
RoubenoffR., McDermottA., WeissL., SuriJ., WoodM., BlochR., & GorbachS.Short-term progressive resistance training increases strength and lean body mass in adults infected with human immunodeficiency virus. AIDS1999; 13: 231–239.
130.
YarasheskiK.E., TebasP., StanersonB., MarinD., ClaxtonS., KennedyM., TantisiriwatW., & PowderlyW.G.Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy.Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 54.
131.
BehrensG., StollM., & SchmidtR.Lipodystrophy syndrome in HIV infection. Drug Safety2000; 23: 57–76.
